Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100XB0H
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥810m2024-10-01 → 2025-09-30StandaloneNet sales
Revenue¥769m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥662m2022-10-01 → 2023-09-30vStandaloneNet sales (5-year summary)
Revenue¥634m2021-10-01 → 2022-09-30vStandaloneNet sales (5-year summary)
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2024-10-01 → 2025-09-30StandaloneOperating income
Operating income−¥1.4bn2023-10-01 → 2024-09-30StandaloneOperating income
Ordinary income−¥1.3bn2024-10-01 → 2025-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2024-10-01 → 2025-09-30StandaloneIncome before income taxes
Profit before tax−¥1.3bn2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Net income−¥1.4bn2024-10-01 → 2025-09-30StandaloneProfit loss
Net income−¥1.3bn2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneNet income loss (5-year summary)
Net income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneNet income loss (5-year summary)
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Total assets¥4.3bnat 2025-09-30StandaloneAssets
Total assets¥5.7bnat 2024-09-30StandaloneAssets
Total assets¥5.6bnat 2023-09-30vStandaloneTotal assets (5-year summary)
Total assets¥6.1bnat 2022-09-30vStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥476mat 2025-09-30StandaloneLiabilities
Total liabilities¥509mat 2024-09-30StandaloneLiabilities
Net assets / equity¥3.8bnat 2025-09-30StandaloneNet assets
Net assets / equity¥5.2bnat 2024-09-30StandaloneNet assets
Net assets / equity¥5.0bnat 2023-09-30vStandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30vStandaloneNet assets (5-year summary)
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2025-09-30StandaloneCash and deposits
Cash and deposits¥4.7bnat 2024-09-30StandaloneCash and deposits
Cash & equivalents¥2.7bnat 2025-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.7bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2023-09-30vStandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.4bn2024-10-01 → 2025-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥565m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥65m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥3m2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥20m2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-5.152024-10-01 → 2025-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.042023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥14.27at 2025-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥19.62at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥21.64at 2023-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio88.8%at 2025-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2023-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-30.4%2024-10-01 → 2025-09-30StandaloneRate of return on equity (5-year summary)
ROE-25.0%2023-10-01 → 2024-09-30StandaloneRate of return on equity (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30vStandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30vStandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued264,729,198at 2025-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued264,515,306at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued232,160,757at 2023-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees107at 2025-09-30StandaloneNumber of employees
Employees112at 2024-09-30StandaloneNumber of employees
Employees98at 2023-09-30vStandaloneNumber of employees
Employees96at 2022-09-30vStandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-10-01 → 2025-09-30¥4m
Reconciling Itemsreconcilingdepreciation2024-10-01 → 2025-09-30¥15m
Reconciling Itemsreconcilingsegment assetsat 2025-09-30¥3.4bn
Reconciling Itemsreconcilingsegment profit2024-10-01 → 2025-09-30−¥563m
Cellular And Tissue Based Product Businessreportable segmentcapex2024-10-01 → 2025-09-30¥3m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥22m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2025-09-3016 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2025-09-30¥139m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥408m
Contracted Cell Manufacturing Businessreportable segmentcapex2024-10-01 → 2025-09-30¥20m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥64m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2025-09-3078 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2025-09-30¥687m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥475m
—segment totalcapex2024-10-01 → 2025-09-30¥24m
—segment totaldepreciation2024-10-01 → 2025-09-30¥86m
—segment totalrevenue2024-10-01 → 2025-09-30¥810m
—segment totalrevenue external2024-10-01 → 2025-09-30¥810m
—segment totalsegment assetsat 2025-09-30¥826m
—segment totalsegment profit2024-10-01 → 2025-09-30−¥883m
Reconciling Itemsreconcilingcapex2023-10-01 → 2024-09-30¥2m
Reconciling Itemsreconcilingdepreciation2023-10-01 → 2024-09-30¥18m
Reconciling Itemsreconcilingsegment assetsat 2024-09-30¥4.9bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2024-09-30−¥577m
Cellular And Tissue Based Product Businessreportable segmentcapex2023-10-01 → 2024-09-30¥21m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥36m
Cellular And Tissue Based Product Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2024-09-30¥116m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥435m
Contracted Cell Manufacturing Businessreportable segmentcapex2023-10-01 → 2024-09-30¥23m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥61m
Contracted Cell Manufacturing Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2024-09-30¥667m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥374m
—segment totalcapex2023-10-01 → 2024-09-30¥44m
—segment totaldepreciation2023-10-01 → 2024-09-30¥97m
—segment totalrevenue2023-10-01 → 2024-09-30¥769m
—segment totalrevenue external2023-10-01 → 2024-09-30¥769m
—segment totalsegment assetsat 2024-09-30¥783m
—segment totalsegment profit2023-10-01 → 2024-09-30−¥808m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 961
ItemContextValueUnit
Provision for share based payments nclCurrentYearInstant_NonConsolidatedMember65646000JPY
Other nclPrior1YearInstant_NonConsolidatedMember－JPY
Other nclCurrentYearInstant_NonConsolidatedMember88000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember240342000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember243387000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember509264000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember476497000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember6486162000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember5102250000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember1327182000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember3850000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember1327182000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember3850000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember-2714945000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember-1362138000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-2714945000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember-1362138000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-4000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-4000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember5098395000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember3743957000JPY
Valuation difference on available for sale securitiesPrior1YearInstant_NonConsolidatedMember92370000JPY
Valuation difference on available for sale securitiesCurrentYearInstant_NonConsolidatedMember33615000JPY
Valuation and translation adjustmentsPrior1YearInstant_NonConsolidatedMember92370000JPY
Valuation and translation adjustmentsCurrentYearInstant_NonConsolidatedMember33615000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember5190766000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember3777572000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember5700031000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember4254070000JPY
Net salesPrior1YearDuration_NonConsolidatedMember768501000JPY
Net salesCurrentYearDuration_NonConsolidatedMember810291000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember655808000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember700570000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember112692000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember109721000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember1497483000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember1555163000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-1384790000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1445442000JPY
Interest income noiPrior1YearDuration_NonConsolidatedMember7026000JPY
Interest income noiCurrentYearDuration_NonConsolidatedMember16933000JPY
Gain on investments in partnership noiPrior1YearDuration_NonConsolidatedMember73196000JPY
Gain on investments in partnership noiCurrentYearDuration_NonConsolidatedMember41032000JPY
Reversal of allowance for doubtful accounts noiPrior1YearDuration_NonConsolidatedMember37200000JPY
Reversal of allowance for doubtful accounts noiCurrentYearDuration_NonConsolidatedMember37010000JPY
Income for cancellation of manufacturing noiPrior1YearDuration_NonConsolidatedMember10042000JPY
Income for cancellation of manufacturing noiCurrentYearDuration_NonConsolidatedMember8517000JPY
Other noiPrior1YearDuration_NonConsolidatedMember2995000JPY
Other noiCurrentYearDuration_NonConsolidatedMember5004000JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember130460000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-09-30pass rounding
balance sheet identitynon_consolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · net assetsnon_consolidated 2025-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass
statement vs summary · total assetsnon_consolidated 2025-09-30pass